Northern Institute for Cancer Research, Paul O'Gorman Building, Newcastle University, Framlington Place, Newcastle Upon Tyne, NE2 4HH, UK.
Br J Cancer. 2010 Aug 10;103(4):439-45. doi: 10.1038/sj.bjc.6605821. Epub 2010 Jul 27.
The last 15 years has seen an explosion of interest in the cancer stem cell (CSC). Although it was initially believed that only a rare population of stem cells are able to undergo self-renewing divisions and differentiate to form all populations within a malignancy, a recent work has shown that these cells may not be as rare as thought first, at least in some malignancies. Improved experimental models are beginning to uncover a less rigid structure to CSC biology, in which the concepts of functional plasticity and clonal evolution must be incorporated into the traditional models. Slowly the genetic programmes and biological processes underlying stem cell biology are being elucidated, opening the door to the development of drugs targeting the CSC. The aim of ongoing research to understand CSCs is to develop novel stem cell-directed treatments, which will reduce therapy resistance, relapse and the toxicity associated with current, non-selective agents.
在过去的 15 年中,人们对癌症干细胞 (CSC) 的兴趣激增。尽管最初人们认为只有少数干细胞能够进行自我更新分裂,并分化为恶性肿瘤中的所有细胞群,但最近的研究表明,这些细胞可能不像最初想象的那样稀有,至少在某些恶性肿瘤中是这样。改进后的实验模型开始揭示 CSC 生物学中较为灵活的结构,其中功能可塑性和克隆进化的概念必须被纳入传统模型中。慢慢地,干细胞生物学背后的遗传程序和生物学过程正在被阐明,为开发针对 CSC 的药物开辟了道路。目前正在进行的旨在了解 CSC 的研究旨在开发新型的针对干细胞的治疗方法,以降低与当前非选择性药物相关的治疗抵抗、复发和毒性。